Pulmatrix, INC

Pulmatrix reported first quarter 2026 financial results, highlighted by a proposed merger with Eos SENOLYTIX and a $1 million private placement.

Pulmatrix, Inc. announced the successful closing of a private placement of Series B Convertible Preferred Stock, raising approximately $1 million as a component of its planned merger with Eos SENOLYTIX, Inc.

Pulmatrix, Inc. announced a definitive merger agreement to acquire Eos SENOLYTIX, Inc., pivoting to novel mitochondrial therapies for aging-related diseases, with existing Pulmatrix shareholders retaining approximately 6% ownership of the combined entity.

Pulmatrix, Inc. announced the termination of its planned merger with Cullgen Inc. due to regulatory delays, and is now actively pursuing alternative merger opportunities.

Pulmatrix, Inc. announced its 2025 financial results and is actively pursuing licensing or monetization of its iSPERSE technology and clinical assets while the proposed merger with Cullgen awaits regulatory approval.

Pulmatrix and Cullgen have mutually waived a merger clause, allowing both companies to explore alternative transactions while awaiting China Securities Regulatory Commission approval for their proposed merger.

Pulmatrix, Inc. reported its Q1 2026 results, detailing a proposed merger with Eos SENOLYTIX, Inc. and concurrent private financings totaling $19 million.

Pulmatrix reports Q3 2025 results, highlighting significant financial shifts and ongoing uncertainty surrounding its proposed merger with Cullgen Inc. and the need for regulatory approval.

Pulmatrix, a biopharmaceutical company, reported a reduced net loss in Q2 2025, driven by lower operating expenses, as its proposed merger with Cullgen Inc. faces a 60-day extension due to pending Chinese regulatory approval.

Pulmatrix reports its Q1 2025 financial results while navigating a planned merger with Cullgen and exploring opportunities to monetize existing clinical assets.

Pulmatrix's Q3 2024 results show a revenue increase due to a contract modification with Cipla, alongside reduced operating expenses following a strategic transaction with MannKind.

Pulmatrix has entered into agreements with MannKind Corporation to sell its lab assets, assign its lease, and cross-license intellectual property, marking a significant strategic shift for the company.

Pulmatrix, Inc. filed an amended annual report to correct a typographical error and provided updated financial statements showing reduced operating expenses and net loss, while awaiting critical regulatory approval for its merger with Cullgen Inc.

Pulmatrix is shifting its strategic focus to a merger with Cullgen Inc., pausing all internal drug development while seeking to monetize its existing iSPERSE-based assets.

Pulmatrix, Inc. outlines its strategic review process, merger agreement with Cullgen Inc., and financial results for the year ended December 31, 2024, highlighting ongoing efforts to monetize clinical assets and manage financial challenges.

Pulmatrix, Inc. released its 2023 annual report, detailing financial results and progress on its inhaled therapeutic pipeline, including updates on PUR3100, PUR1800, and PUR1900.

Eos SENOLYTIX reports positive preclinical results for its lead geropeptide candidate, PTC-2105, ahead of its merger with Pulmatrix.

Pulmatrix and Eos SENOLYTIX announce a definitive merger agreement to create a leading anti-aging biotechnology company, Eos SENOLYTIX, supported by $19 million in concurrent financings.

Pulmatrix, Inc. stockholders have overwhelmingly approved all proposals related to the previously announced merger with Cullgen Inc., including the issuance of shares, a reverse stock split, and an increase in authorized common stock, though the merger remains subject to China Securities Regulatory Commission (CSRC) approval.

Cullgen has begun dosing human subjects in a Phase 1 trial for its oral pan-TRK protein degrader, CG001419, aimed at treating acute and chronic pain, marking its second clinical program.

Pulmatrix, Inc. will hold its annual stockholder meeting virtually on December 18, 2024, to elect directors and ratify the appointment of its independent accounting firm.

RCM Eos PIPE HOLDINGS, LLC has acquired $1 million in Series B Preferred Stock to provide interim financing for the pending merger with Eos SENOLYTIX, Inc.